Cipla Ltd.

NSE: CIPLA | BSE: 500087 | ISIN: INE059A01026 | Industry: Pharmaceuticals
| Mid-range Performer
1503.3000 15.30 (1.03%)
NSE Sep 30, 2025 15:31 PM
Volume: 1.0M
 

logo
Cipla Ltd.
08 Feb 2018
1503.30
1.03%
Reliance Securities
Valuation Continues to Remain Pricey; Maintain HOLD Cipla's revenue rose by 7.3% YoY to Rs39.1bn in 3QFY18 vs. our estimates of Rs41.6bn. While its US business declined by 1.8% YoY to US$100mn, domestic business grew by 14.5% YoY (+22% YoY adjusted for GST-related accounting). Its South African business grew by 6.1% YoY to Rs8.7bn, while Emerging Market sales dipped by 11.7% YoY to Rs3.7bn. In-line with our estimates, EBITDA rose by 20.8% YoY led by lower operating expenses. Gross margin rose by 281bps QoQ due to better product-mix. EBITDA margin improved by 234bps YoY to 20.9%. We believe Cipla's valuation continues to remain expensive. Rolling over our estimates to FY20E, we maintain...
Cipla Ltd. is trading above its 200 day SMA of 1495.4
More from Cipla Ltd.
Recommended